Outpatient treatment of venous thromboembolism using low molecular weight heparins: An overview

International Angiology

Volumn 23, Issue 4, 2004, Pages 305-316

  Matsagas, M I ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Low molecular weight heparin; Thromboembolism; Venous thrombosis

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE COST; HOME CARE; HUMAN; INTERPERSONAL COMMUNICATION; OUTPATIENT CARE; PATIENT CARE; PATIENT EDUCATION; PATIENT SATISFACTION; PATIENT SELECTION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; OUTPATIENT; SAFETY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; OUTPATIENTS; SAFETY; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 23044443248     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:19-16.
2. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(1 Suppl):176S-93S.
3. Yusen RD, Haraden BM, Gage BF, Woodward RS, Rubin BG, Botney MD. Criteria for outpatient management of proximal lower extremity deep venous thrombosis. Chest 1999;115:972-9.
4. Hirsh J, Lee AYY. How we diagnose and treat deep vein thrombosis. Blood 2002;99:3102-10.
5. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:14-8.
6. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585.
7. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
8. Nicolaides AN, Kakkar VV, Field ES, Renney JT. The origin of deep vein thrombosis: a venographic study. Br J Radiol 1971;44:653-63.
9. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:122-30.
10. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-8.
11. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
12. Anderson FA Jr, Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 1992;16:707-14.
13. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-7.
14. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
15. Merli GJ. Low molecular weight heparin in the treatment of acute deep vein thrombosis and pulmonary embolism: a paradigm change in care. J Thromb Thrombolysis 2000;9 Suppl 1:521-7.
16. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(1 Suppl):64S-94S.
17. Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987;57:97-101.
18. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-9.
19. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
20. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
21. Kirchmaier CM, Wolf H, Schafer H, Ehlers B, Breddin HK. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with-intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group. Int Angiol 1998;17:135-45.
22. Meyer G, Brenot F, Pacouret G, Simonneau G, Gillet Juvin K, Charbonnier B et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995;74:1432-5.
23. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
24. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-77.
25. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
26. Dunn AS, Coller B. Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 1999;106:660-9.
27. Boccalon H, Elias A, Chale JJ, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med 2000;160:1769-73.
28. Schraibman IG, Milne AA, Royle EM. Home versus inpatient treatment for deep vein thrombosis (Cochrane Review). The Cochrane Library, Issue 3, 2003: Oxford: Update Software.
29. Dunn AS, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks HS et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001;110:458-62.
30. Ageno W, Steidl L, Marchesi C, Dentali F, Mera V, Squizzato A et al. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Haematologica 2002;87:286-91.
31. Lapidus L, Borretzen J, Fahlen M, Thomsen HG, Hasselblom S, Larson L et al. Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients. Pathophysiol Haemost Thromb 2002;32:59-66.
32. van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis-an economic evaluation. TASMAN Study Group. Thromb Haemost 1998;79:259-63.
33. Wells PS. Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism. Curr Opin Pulm Med 2001;7:360-4.
34. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158:2001-3.
35. Rose P, Bell D, Green ES, Davenport A, Fegan C, Grech H et al. The outcome of ambulatory DVT management using a multidisciplinary approach. Clin Lab Haematol 2001;23:301-6.
36. Blattler W, Kreis N, Blattler IK. Practicability and quality of outpatient management of acute deep venous thrombosis. J Vasc Surg 2000;32:855-60.
37. O'Shaughnessy D, Miles J, Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. QJM 2000;93:663-7.
38. Mattiasson I, Berntorp E, Bornhov S, Lagerstedt C, Lethagen S, Persson J et al. Out-patient treatment of acute deep vein thrombosis. Int Angiol 1998;17:146-50.
39. Schwarz T, Schmidt B, Beyer J, Schroder HE, Schellong SM. Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients. J Vasc Surg 2001;34:1065-70.
40. Vinson DR, Berman DA. Outpatient treatment of deep venous thrombosis: a clinical care pathway managed by the emergency department. Ann Emerg Med 2001;37:251-8.
41. Rymes NL, Lester W, Connor C, Chakrabarti S, Fegan CD. Outpatient management of DVT using low molecular weight heparin and a hospital outreach service. Clin Lab Haematol 2002;24:165-70.
42. Tanvetyanon T, Cohn JB. Eligibility for outpatient treatment with low-molecular-weieht heparin in venous thromboembolism. Arch Intern Med 2000;160:869-70.
43. Dedden P, Chang B, Nagel D. Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin. Am J Health Syst Pharm 1997;54:1968-72.
44. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158:1809-12.
45. Vanscoy GJ. Outpatient management of venous thromboembolism. J Thromb Thrombolysis 1999;7:109-12.
46. Kearon C, Gent M. Heparin therapy for deep vein thrombosis: from hospital to home. Am J Med 2001;110:501-2.
47. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000;83:209-11.
48. Liebowitz RS. Deep venous thrombosis: thinking inside out. Arch Intern Med 1998;158:1964.
49. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159:2298-304.
50. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-32.
51. Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002;122:108-14.
52. Bick RL. Therapy for venous thrombosis: guidelines for a competent and cost-effective approach. Clin Appl Thromb Hemost 1999;5:2-9.
53. Kwong NM. Workshop: Implementation of home treatment programs for deep vein thrombosis with low molecular weight heparin. J Thromb Thrombolysis 2000;9 Suppl 1:S53-4.
54. Kelly J, Rudd A, Lewis RR, Hunt BJ. Plasma D-dimers in the diagnosis of venous thromboembolism. Arch Intern Med 2002;162:747-56.
55. Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA et al. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med 1999;160:1043-66.
56. Kearon C, Ginsberg JS, Douketis J, Crowther M, Brill-Edwards P, Weitz JI et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med 2001;135:108-11.
57. Schutgens RE, Esseboom EU, Haas FJ, Niemvenhuis HK, Biesma DH. Usefulness of a semiquantitative D-dimer test for the exclusion of deep venous thrombosis in outpatients. Am J Med 2002;112:617-21.
58. Goldhaber SZ. Pulmonary embolism. Lancet 2004;363:1295-305.
59. Kearon C. Diagnosis of pulmonary embolism. CMAJ 2003;168:183-94.
60. Partsch H, Kechavarz B, Kohn H, Mostbeck A. The effect of mobilisation of patients during treatment of thromboembolic disorders with low-molecular-weight heparin. Int Angiol 1997;16:189-92.
61. Partsch H, Kechavarz B, Mostbeck A, Kohn H, Lipp C. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. J Vasc Surg 1996;24:774-82.
62. Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. Vasc 2001;30:195-204.
63. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
64. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res 2001;102:V187-94.
65. Lee AY. Treatment of venous thromboembolism in cancer patients. Thromb Res 2001;102:V195-208.
66. Piccioli A, Prandoni P. Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost 2003;1:2271-2.
67. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668-72.
68. Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002;100:3470-8.